Mauricio Tohen, MD
Psychiatry · Albuquerque, NMNPI 1326256561
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $129,328 of the $159,783 with a category attached, or 80.9%. 10 manufacturers reported payments, led by Alkermes, Inc. at 40.9% of the total. Reporting peaked in 2023 at $48,377 and has fallen 55.1% since, to $21,697 in 2025. Among psychiatry clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 121 payments — averaging $1320.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$65K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$33K
- Merck$16K
- H. Lundbeck A S$15K
- E.r. Squibb & Sons, L.L.C.$8K
- AbbVie$7K
- plus $15K from 4 others
What the payments were for
- Consulting fees$129,32881%
- Speaking & faculty fees$18,52612%
- Travel & lodging$9,5756%
- Food & beverage$2,2681%
- Education$870%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 25 | $65,425 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 40 | $33,416 |
| Merck | 13 | $15,934 |
| H. Lundbeck A S | 14 | $14,547 |
| E.r. Squibb & Sons, L.L.C. | 11 | $8,367 |
| AbbVie(2 entities) | 9 | $7,334 |
| Neurocrine Biosciences, Inc. | 1 | $6,300 |
| Otsuka America Pharmaceutical, Inc. | 4 | $3,780 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $3,105 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $1,575 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$73,945
- ABILIFY MAINTENA$25,109
- ABILIFY ASIMTUFII$10,287
- INGREZZA$6,300
- REXULTI$6,174
- CAPLYTA$3,105
- VRAYLAR$497
How this compares
$159,783 in reported general payments places this provider in the 95th percentile of 174 psychiatry providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Asenapine Maleate | 12 | $2,057 |
| Desipramine Hcl | 11 | $1,052 |
| Gabapentin | 22 | $300 |
| Liothyronine Sodium | 12 | $92 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Albuquerque
- Patricio EscalonaAlbuquerque$487K
- Shiva SharmaAlbuquerque$140K
- Javier VeraAlbuquerque$8K
- Nancy MartinAlbuquerque$6K
- Reuben SutterAlbuquerque$5K
- Swala AbramsAlbuquerque$3K
- David EarlAlbuquerque$3K
- Ronald RomanikAlbuquerque$2K
- Anthony HolzgangAlbuquerque$2K
- Mahvish KhanAlbuquerque$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.